Cargando…

Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2

Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine development. They are robust, safe, versatile and highly immunogenic supra-molecular structures that closely mimic the native conformation of viruses without carrying their genetic material. HIV-1 Gag VLPs share simil...

Descripción completa

Detalles Bibliográficos
Autores principales: Boix-Besora, Arnau, Lorenzo, Elianet, Lavado-García, Jesús, Gòdia, Francesc, Cervera, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874421/
https://www.ncbi.nlm.nih.gov/pubmed/35214708
http://dx.doi.org/10.3390/vaccines10020250
_version_ 1784657684233977856
author Boix-Besora, Arnau
Lorenzo, Elianet
Lavado-García, Jesús
Gòdia, Francesc
Cervera, Laura
author_facet Boix-Besora, Arnau
Lorenzo, Elianet
Lavado-García, Jesús
Gòdia, Francesc
Cervera, Laura
author_sort Boix-Besora, Arnau
collection PubMed
description Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine development. They are robust, safe, versatile and highly immunogenic supra-molecular structures that closely mimic the native conformation of viruses without carrying their genetic material. HIV-1 Gag VLPs share similar characteristics with wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, making them a suitable platform for the expression of its spike membrane protein to generate a potential vaccine candidate for COVID-19. This work proposes a methodology for the generation of SARS-CoV-2 VLPs by their co-expression with HIV-1 Gag protein. We achieved VLP functionalization with coronavirus spike protein, optimized its expression using a design of experiments (DoE). We also performed the bioprocess at a bioreactor scale followed by a scalable downstream purification process consisting of two clarifications, an ion exchange and size-exclusion chromatography. The whole production process is conceived to enhance its transferability at current good manufacturing practice (cGMP) industrial scale manufacturing. Moreover, the approach proposed could be expanded to produce additional Gag-based VLPs against different diseases or COVID-19 variants.
format Online
Article
Text
id pubmed-8874421
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88744212022-02-26 Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2 Boix-Besora, Arnau Lorenzo, Elianet Lavado-García, Jesús Gòdia, Francesc Cervera, Laura Vaccines (Basel) Article Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine development. They are robust, safe, versatile and highly immunogenic supra-molecular structures that closely mimic the native conformation of viruses without carrying their genetic material. HIV-1 Gag VLPs share similar characteristics with wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, making them a suitable platform for the expression of its spike membrane protein to generate a potential vaccine candidate for COVID-19. This work proposes a methodology for the generation of SARS-CoV-2 VLPs by their co-expression with HIV-1 Gag protein. We achieved VLP functionalization with coronavirus spike protein, optimized its expression using a design of experiments (DoE). We also performed the bioprocess at a bioreactor scale followed by a scalable downstream purification process consisting of two clarifications, an ion exchange and size-exclusion chromatography. The whole production process is conceived to enhance its transferability at current good manufacturing practice (cGMP) industrial scale manufacturing. Moreover, the approach proposed could be expanded to produce additional Gag-based VLPs against different diseases or COVID-19 variants. MDPI 2022-02-07 /pmc/articles/PMC8874421/ /pubmed/35214708 http://dx.doi.org/10.3390/vaccines10020250 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Boix-Besora, Arnau
Lorenzo, Elianet
Lavado-García, Jesús
Gòdia, Francesc
Cervera, Laura
Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
title Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
title_full Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
title_fullStr Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
title_full_unstemmed Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
title_short Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
title_sort optimization, production, purification and characterization of hiv-1 gag-based virus-like particles functionalized with sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874421/
https://www.ncbi.nlm.nih.gov/pubmed/35214708
http://dx.doi.org/10.3390/vaccines10020250
work_keys_str_mv AT boixbesoraarnau optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2
AT lorenzoelianet optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2
AT lavadogarciajesus optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2
AT godiafrancesc optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2
AT cerveralaura optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2